Back to Search
GENEVIEVE NORONHA, PHARM.D, BCPS
PHARM.D, BCPS
Pharmacist
NPI: 1811593213Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
24971(MD)
Research & Publications (16)
Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
PMID 19056934·J Pharmacol Exp Ther·2009
7-preclinical
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.
PMID 18483622·J Clin Invest·2008
7-preclinical
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
PMID 18394554·Cancer Cell·2008
7-preclinical
Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.
PMID 18330892·J Cell Physiol·2008
7-preclinical
Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration.
PMID 18311895·J Med Chem·2008
7-preclinical
Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
PMID 18394555·Cancer Cell·2008
7-preclinical
Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.
PMID 17685602·J Med Chem·2007
7-preclinical
The design and preliminary structure-activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes.
PMID 17827012·Bioorg Med Chem Lett·2007
8-other
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
PMID 17541402·Leukemia·2007
7-preclinical
Metabolism and pharmacokinetics of a novel Src kinase inhibitor TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) and its active N-oxide metabolite TG100855 ([7-(2,6-dichloro-phenyl)-5-methylbenzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine).
PMID 17371799·Drug Metab Dispos·2007
4-observational
Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.
PMID 17371238·Biochem Soc Trans·2007
7-preclinical
Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.
PMID 17113292·Bioorg Med Chem Lett·2007
7-preclinical
Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.
PMID 16931012·Bioorg Med Chem Lett·2006
8-other
Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
PMID 17172449·Proc Natl Acad Sci U S A·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 2401 W BELVEDERE AVE
BALTIMORE, MD 21215 - Phone
- (617) 306-2995
Quick Facts
- NPI
- 1811593213
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 2
- Publications
- 16
Are you this provider?
Claim Your Profile